SELLAS Life Sciences Group (SLS) is entering its latest earnings print with one of the most aggressive short-interest setups in the small-cap biotech sector. According to Ortex data, 39% of the company's free float is currently held short. The lending market for the stock is described as almost fully locked, indicating significant difficulty for new shorts to enter or existing ones to maintain positions without high costs. The stock has already faced a 33% decline, reflecting the intense bearish sentiment surrounding the upcoming financial results.
Signal data sourced from Ortex. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.